Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit

摘要

MET aberrations were associated with adverse tumor pathologic features, such as high grade and hormone receptor negativity in a cohort of breast cancer patients referred to a Phase I program. Additionally, patients with MET aberrations had inferior overall survival from Phase I consult compared with wild-type patients. These findings are quite provocative, identifying a subset of patients at a particularly high risk for worse survival outcomes.Backgroundc-MET is a receptor tyrosine kinase whose phosphorylation activates important proliferation pathways. MET amplification and mutation have been described in various malignancies, including breast cancer (BC), and c-MET overexpression is associated with worse survival outcomes in patients with BC. We describe MET mutation and amplification rates in a BC cohort of patients referred to a Phase I Unit.